Synlogic announces appointment of general counsel and corporate secretary

Cambridge, mass., june 29, 2022 (globe newswire) -- synlogic, inc. (nasdaq: sybx), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of brendan st. amant as general counsel and corporate secretary effective july 1, 2022.

SYBX Ratings Summary

SYBX Quant Ranking